NCT04483674UNKNOWNPhase 2The purpose of this study is to assess the efficacy of Bictegravir/FTC/TAF in patients with less of 100 days post HIV infection
No linked publications found in PubMed
Inclusion Criteria: * Male and female patients aged 18-65 years * ART naïve * HIV infection of less than 100 days post-infection (documented 3 month previous negative serology or incomplete WB test with negative p31 band) * Women of child-bearing potential must have a negative pregnancy test in serum before the inclusion in the study and agree to use highly effective contraceptive methods, including intrauterine device, bilateral tubal occlusion or a vasectomized partner. Exclusion Criteria: * Known hypersensitivity to any drug included in Bictegravir/FTC/TAF regimen * AST \>5 times UNL * Creatinine Clearance \<30 mL/min/1.73m2 * Any end-stage organ disease * Acute or chronic HCV co-infection * Use of PrEP with Truvada® until 4 weeks before the onset of symptoms of PHI (risk of acquired-drug resistance to FCT or TDF).